source
- AstraZeneca reportedly bids $10 billion for metabolic biotech Rhythm PharmaceuticalsAstraZeneca is said to have made a $10 billion offer to acquire Rhythm Pharmaceuticals, a biotech that develops treatments for rare neuroendocrine disorders. The proposal values Rhythm at $124 per…
- Revolution Medicines' Rasonque generates $198 million in sales within five weeks of U.S. approvalRevolution Medicines reported that its pancreatic cancer therapy Rasonque has achieved $198 million in revenue in the first five weeks after receiving U.S. approval. The company said more than 5,00…